Pfizer Presents Positive Phase 3 Data at the 28th Congress of the European Academy of Dermatology and Venereology for Abrocitinib in Moderate to Severe Atopic Dermatitis | Small Molecules | News Channels - PipelineReview.com
What’s next for rheumatoid arthritis and cannabis? The GrowthOp One-and-a-half million people in the United States suffer from rheumatoid arthritis (RA). In fact, The Arthritis Foundation estimates that three times as many ...
Comments
Post a Comment